NEW CRYOPRESERVATION TECHNOLOGY OF HMSCS: FIRST PRECLINICAL
RESULTS USING DMSO-CONTAINING MEDIUM

J 2020

NEW CRYOPRESERVATION TECHNOLOGY OF HMSCS: FIRST PRECLINICAL RESULTS USING DMSO-CONTAINING MEDIUM

JANDOVA, M., P. SPONER, D. VOKURKOVA, P. O. BAUER, A. FILIPOVA et. al.

Základní údaje

Originální název

NEW CRYOPRESERVATION TECHNOLOGY OF HMSCS: FIRST PRECLINICAL RESULTS USING DMSO-CONTAINING MEDIUM

Autoři

JANDOVA, M., P. SPONER, D. VOKURKOVA, P. O. BAUER, A. FILIPOVA, S. FILIP a P. MERICKA

Vydání

CryoLetters, LONDON, CRYO LETTERS, 2020, 0143-2044

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30230 Other clinical medicine subjects

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.066

UT WoS

000527407900009

Klíčová slova anglicky

mesenchymal stem cells; advanced therapy medicinal product; dimethyl sulfoxide; cryopreservation

Štítky

Excelence Science, FN HK, RIV, user

Změněno: 7. 12. 2021 13:01, Bc. Hana Vladíková, BBA

Anotace

V originále

BACKGROUND: Human mesenchymal stem cells (hMSCs) have tremendous potential in regenerative medicine, making it desirable to cryopreserve and bank them to increase their access and availability. OBJECTIVE: This research is part of a clinical trial performed on six patients that aimed to use advanced therapy medicinal products (ATMPs) based on hMSCs in patients undergoing repeated total hip replacement. MATERIALS AND METHODS: To compare the characteristics of fresh and frozen hMSCs, we used the trypan blue exclusion test (cell viability), flow cytometry (cell viability and phenotyping), sterility determinations and the clonogenic assay of cell proliferation. RESULTS: Cryopreserved hMSCs showed good quality parameters after thawing in comparison with fresh hMSCs in suspension. When using a medium containing dimethyl sulfoxide (DMSO), the viability was higher than 90% in all cases. The cell purity determined by flow cytometry was also acceptable. CONCLUSION: These initial results show that the prepared cryopreserved ATMP exhibited good viability and phenotype characteristics.

Návaznosti

90128, velká výzkumná infrastruktura

Název: CZECRIN III

Citovat

JANDOVA, M., P. SPONER, D. VOKURKOVA, P. O. BAUER, A. FILIPOVA, S. FILIP a P. MERICKA. NEW CRYOPRESERVATION TECHNOLOGY OF HMSCS: FIRST PRECLINICAL RESULTS USING DMSO-CONTAINING MEDIUM. CryoLetters. LONDON: CRYO LETTERS, 2020, roč. 41, č. 1, s. 50-56. ISSN 0143-2044.

@article{1807986,
   author = {Jandova, M. and Sponer, P. and Vokurkova, D. and Bauer, P. O. and Filipova, A. and Filip, S. and Mericka, P.},
   article_location = {LONDON},
   article_number = {1},
   keywords = {mesenchymal stem cells; advanced therapy medicinal product; dimethyl sulfoxide; cryopreservation},
   language = {eng},
   issn = {0143-2044},
   journal = {CryoLetters},
   title = {NEW CRYOPRESERVATION TECHNOLOGY OF HMSCS: FIRST PRECLINICAL RESULTS USING DMSO-CONTAINING MEDIUM},
   url = {https://www.webofscience.com/wos/woscc/full-record/WOS:000527407900009},
   volume = {41},
   year = {2020}
}

TY  - JOUR
ID  - 1807986
AU  - Jandova, M. - Sponer, P. - Vokurkova, D. - Bauer, P. O. - Filipova, A. - Filip, S. - Mericka, P.
PY  - 2020
TI  - NEW CRYOPRESERVATION TECHNOLOGY OF HMSCS: FIRST PRECLINICAL RESULTS USING DMSO-CONTAINING MEDIUM
JF  - CryoLetters
VL  - 41
IS  - 1
SP  - 50-56
EP  - 50-56
PB  - CRYO LETTERS
SN  - 01432044
KW  - mesenchymal stem cells
KW  - advanced therapy medicinal product
KW  - dimethyl sulfoxide
KW  - cryopreservation
UR  - https://www.webofscience.com/wos/woscc/full-record/WOS:000527407900009
N2  - BACKGROUND: Human mesenchymal stem cells (hMSCs) have tremendous potential in regenerative medicine, making it desirable to cryopreserve and bank them to increase their access and availability. OBJECTIVE: This research is part of a clinical trial performed on six patients that aimed to use advanced therapy medicinal products (ATMPs) based on hMSCs in patients undergoing repeated total hip replacement. MATERIALS AND METHODS: To compare the characteristics of fresh and frozen hMSCs, we used the trypan blue exclusion test (cell viability), flow cytometry (cell viability and phenotyping), sterility determinations and the clonogenic assay of cell proliferation. RESULTS: Cryopreserved hMSCs showed good quality parameters after thawing in comparison with fresh hMSCs in suspension. When using a medium containing dimethyl sulfoxide (DMSO), the viability was higher than 90% in all cases. The cell purity determined by flow cytometry was also acceptable. CONCLUSION: These initial results show that the prepared cryopreserved ATMP exhibited good viability and phenotype characteristics.
ER  -

JANDOVA, M., P. SPONER, D. VOKURKOVA, P. O. BAUER, A. FILIPOVA, S. FILIP a P. MERICKA. NEW CRYOPRESERVATION TECHNOLOGY OF HMSCS: FIRST PRECLINICAL RESULTS USING DMSO-CONTAINING MEDIUM. \textit{CryoLetters}. LONDON: CRYO LETTERS, 2020, roč.~41, č.~1, s.~50-56. ISSN~0143-2044.

Podrobný výpis o publikaci